Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Illinois EC rule challenged

This article was originally published in The Tan Sheet

Executive Summary

A lawsuit challenging the Illinois regulation that requires all pharmacists to dispense emergency contraception was filed by the D.C.-based law group American Center for Law & Justice in Springfield, Ill. District Court Dec. 19. The suit represents five Walgreens pharmacists who were indefinitely suspended or fired for refusing to prescribe EC. The Illinois regulation was introduced as an "emergency rule" by Gov. Rod Blagojevich (D) in April and signed into law in August ("The Tan Sheet" June 20, 2005, p. 11). "This regulation targets religious views and practices in an unconstitutional manner," ACLJ Senior Counsel Francis Manion states in a same-day release...

You may also be interested in...



Plan B Illinois “Emergency Rule” Challenged In Pharmacist Suit

An Illinois "emergency rule" requiring pharmacists to dispense emergency contraceptive Plan B violates the state's Health Care Right of Conscience Act, according to a suit filed in Whiteside County, Ill. court June 8

FTC Commissioner Changes Could Impact Pharma Mergers, Scrutiny Of Biosimilars Uptake

President Biden’s picks to fill two commissioner posts may shift dynamics on pharmaceutical industry enforcement. Rohit Chopra’s nomination to Consumer Financial Protection Bureau removes strong critic of pharma mergers.

Prices Plunge As Xarelto Generics Arrive In India

More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel